157
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Screening approaches against claudin-4 focusing on therapeutics through molecular docking and the analysis of their relative dynamics: a theoretical approach

&
Pages 436-441 | Received 28 Dec 2019, Accepted 29 Mar 2020, Published online: 22 Apr 2020

References

  • Morita K, Sasaki H, Furuse M, et al. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol. 1999;147(1):185–194.
  • Brugge JS. Casting light on focal adhesions. Nat Genet. 1998;19(4):309–311.
  • Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65(21):9603–9606.
  • Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players. Trends Cell Biol. 1999;9(7):268–273.
  • Mineta K, Yamamoto Y, Yamazaki Y, et al. Predicted expansion of the claudin multigene family. FEBS Lett. 2011;585(4):606–612.
  • Turksen K, Troy TC. Barriers built on claudins. J Cell Sci. 2004;117(12):2435–2447.
  • Singh AB, Sharma A, Dhawan P. Claudin family of proteins and cancer: an overview. J Oncol. 2010;2010:1–11.
  • Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2(4):285–293.
  • Hanna PC, Wieckowski EU, Mietzner TA, et al. Mapping of functional regions of clostridium perfringens type A enterotoxin. Infect Immun. 1992;60(5):2110–2114.
  • Briehl MM, Miesfeld RL. Isolation and characterization of transcripts induced by androgen withdrawal and apoptotic cell death in the rat ventral prostate. Mol Endocrinol. 1991;5(10):1381–1388.
  • Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009;1(2):a002584.
  • Koval M. Claudins-key pieces in the tight junction puzzle. Cell Commun Adhes. 2006;13(3):127–138.
  • Li J, Chigurupati S, Agarwal R, et al. Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther. 2009;8(19):1806–1814.
  • Kwon M. Emerging roles of claudins in human cancer. IJMS. 2013;14(9):18148–18180.
  • Litkouhi B, Kwong J, Lot CM, et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia. 2007;9(4):304–314.
  • Aravindakshan J, Chen X, Sairam MR. Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants. Neoplasia. 2006;8(12):984–994.
  • Rambabu M, Jayanthi S. Virtual screening of National Cancer Institute database for claudin‐4 inhibitors: synthesis, biological evaluation, and molecular dynamics studies. J Cell Biochem. 2019;120(5):8588–8600.
  • Nagpal I, Raj I, Subbarao N, et al. Virtual screening, identification and in vitro testing of novel inhibitors of O-acetyl-L-serine sulfhydrylase of Entamoeba histolytica. PLOS One. 2012;7(2):e30305.
  • Banerjee K, Gupta U, Gupta S, et al. Molecular docking of glucosamine-6-phosphate synthase in Rhizopus oryzae. Bioinformation. 2011;7(6):285–290.
  • Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–1749.
  • Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein − ligand complexes. J Med Chem. 2006;49(21):6177–6196.
  • Schrödinger Release 2014-2: Desmond Molecular Dynamics System, version 3.8. Maestro-Desmond Interoperability Tools, version 3.8, Schrödinger [Computer software]. New York (NY): D. E. Shaw Research; 2014.
  • Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79(2):926–935.
  • Small-Molecule Drug Discovery Suite 2015-2: QikProp [Computer software], version 4.4, New York (NY): Schrödinger, LLC; 2015.
  • Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.
  • Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002;54(3):355–366.
  • Langeswaran K, Jeyaraman J, Babu JR, et al. Identifying dual leucine zipper kinase (DLK) inhibitors using e-pharamacophore screening and molecular docking. J Recept Sig Transd. 2019;39(2):99–105.
  • Jayaprakash P, Biswal J, Kanagarajan S, et al. Design of novel Ph MTNA inhibitors, targeting neurological disorder through homology modeling, molecular docking, and dynamics approaches. J Recept Sig Transd. 2019;39(1):28–38.
  • Anbarasu K, Jayanthi S. Designing and optimization of novel human LMTK3 inhibitors against breast cancer–a computational approach. J Recept Sig Transd. 2017;37(1):51–59.
  • Samad FA, Suliman B, Basha SH, et al. A comprehensive in silico analysis on the structural and functional impact of SNPs in the congenital heart defects associated with NKX2-5 gene-A molecular dynamic simulation approach. PLoS One. 2016;11(5):e0153999.
  • Lobanov MY, Bogatyreva NS, Galzitskaya OV. Radius of gyration as an indicator of protein structure compactness. Mol Biol. 2008;42(4):623–628.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.